The in vitro activities of fluconazole and voriconazole against 1,024 clinical isolates of Candida spp. were determined by the agar disk diffusion test using the Clinical and Laboratory Standards Institute (CLSI) M44-A guidelines. The results of this investigation demonstrated the broad-spectrum in vitro activity of voriconazole, relative to that of fluconazole, against yeasts tested, in particular fluconazole-resistant isolates, such as Candida krusei that showed high susceptibility to voriconazole. The situation in Turin, Italy, is quite similar to that of the rest of Italy, reflecting the worldwide trend.
In vitro activity of fluconazole and voriconazole against clinical isolates of Candida spp. determined by disk diffusion testing in Turin (Italy) [*V.Tullio is the corresponding author]
MANDRAS, NarcisaFirst
;TULLIO, Viviana Cristina
;ALLIZOND, VALERIA;SCALAS, Daniela;BANCHE, Giuliana;ROANA, Janira;CUFFINI, Annamaria;CARLONE, NicolaLast
2009-01-01
Abstract
The in vitro activities of fluconazole and voriconazole against 1,024 clinical isolates of Candida spp. were determined by the agar disk diffusion test using the Clinical and Laboratory Standards Institute (CLSI) M44-A guidelines. The results of this investigation demonstrated the broad-spectrum in vitro activity of voriconazole, relative to that of fluconazole, against yeasts tested, in particular fluconazole-resistant isolates, such as Candida krusei that showed high susceptibility to voriconazole. The situation in Turin, Italy, is quite similar to that of the rest of Italy, reflecting the worldwide trend.File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
AAC_2009_Mandras.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
48.18 kB
Formato
Adobe PDF
|
48.18 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.